Results 141 to 150 of about 69,426 (314)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study assesses the 3‐month effectiveness of the calcitonin gene‐related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications. Background Studies comparing the effectiveness of calcitonin gene‐related peptide monoclonal antibodies versus traditional oral migraine preventive medications ...
Richard B. Lipton, Miguel J. A. Láinez, Zubair Ahmed, Carlos Vallarino, Diego Novick, Maurice Vincent, Lars Viktrup, Rebecca L. Robinson   +7 more
wiley   +1 more source

Frequency, Timing, Burden and Recurrence of Adverse Events Following Immunization After HPV Vaccine Based on a Cohort Event Monitoring Study in the Netherlands

Vaccines
Background/Objectives: The aim of this study was to systematically assess Adverse Events Following Immunization (AEFI) among children following administration of the human papillomavirus (HPV) vaccine (Cervarix®) included in the Dutch National ...
Monika Raethke, Jeroen Gorter, Rachel Kalf, Leontine van Balveren, Rana Jajou, Florence van Hunsel   +5 more
doaj   +1 more source

Limitations of FAERS‐based analyses of paternal drug exposure: The critical need for maternal data integration

Andrology, EarlyView.
Mikako Goto, Izumi Fujioka, Yasuha Ogawa, Sachi Koinuma, Koushi Yamaguchi   +4 more
wiley   +1 more source

First successful protocol for desensitization to eptinezumab

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed
Benoit Gerard, Hubert Praudel, Michel Lanteri‐Minet, Elise Van Obberghen, Fanny Rocher‐Moreau, Johanna Rousset, Ulysse Jacquier, Sylvie Leroy, Margot Delin   +8 more
wiley   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, EarlyView.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

Navigating the Complexities of Artificial Intelligence–Enabled Real-World Data Collection for Oncology Pharmacovigilance [PDF]

Jack Gallifant, Leo Anthony Celi, Elad Sharon, Danielle S. Bitterman   +3 more
openalex   +1 more source

Pharmacovigilance [PDF]

, 2017
Michael Kaeding, Julia Schmälter, Christoph Klika   +2 more
  +4 more sources

If treating obesity with GLP‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials

Diabetes, Obesity and Metabolism, EarlyView.
Anastasios Tentolouris, Ioannis Ntanasis‐Stathopoulos   +1 more
wiley   +1 more source

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek, Nathalia Bellon, Stéphanie Mallet, Hélène Aubert, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq‐Thomas, Sébastien Barbarot   +9 more
wiley   +1 more source

Pharmacovigilance

Journal of Drug Research in Ayurvedic Sciences, 2019
Sabrina Nour, Gilles Plourde
  +4 more sources